Talphera (NASDAQ:TLPH) CEO Vincent Angotti Buys 213,310 Shares

Talphera, Inc. (NASDAQ:TLPH) CEO Vincent Angotti acquired 213,310 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were bought at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the transaction, the chief executive officer directly owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. This trade represents a 36.31% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Talphera Trading Up 9.1%

Shares of NASDAQ TLPH opened at $0.80 on Thursday. The stock has a market cap of $37.12 million, a P/E ratio of -2.15 and a beta of 0.47. The business’s fifty day simple moving average is $0.88 and its 200-day simple moving average is $1.05. Talphera, Inc. has a 12-month low of $0.38 and a 12-month high of $1.57.

Talphera (NASDAQ:TLPH) last released its earnings results on Monday, March 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. On average, equities analysts forecast that Talphera, Inc. will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Talphera

Several institutional investors have recently modified their holdings of the company. Group One Trading LLC increased its holdings in Talphera by 3,224.0% in the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC purchased a new stake in Talphera during the 3rd quarter worth about $29,000. Persistent Asset Partners Ltd purchased a new stake in Talphera during the 4th quarter worth about $42,000. Mariner LLC lifted its holdings in Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after buying an additional 33,000 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in shares of Talphera during the 3rd quarter worth about $89,000. 37.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Talphera presently has an average rating of “Hold” and an average target price of $6.00.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.